DeBoRA · Dopamine and Bone Metabolism in Rheumatoid Arthritis
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-09-01 → 2018-08-31
- EU contribution
- €171,461
- Participants
- 1
- Scheme
- MSCA-IF-EF-RI
Lines connect the coordinator with its partners.
Results in brief
Dopamine and Bone Metabolism in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, articular bone erosion and consequently joint destruction that can lead to complete loss of function. RA is not simply a disease of the joints but can affect many other organs and cause, for instance, systemic osteoporosis, a loss of bone mass. Nowadays there are many therapeutics available that can significantly reduce the impact of RA. However, bone destruction and osteoporosis still remains an issue for rheumatologists. Therefore, an efficient long-term therapeutic approach to target bone erosion still need to be established. Final goal of this project was to establish a therapeutic approach to target bone remodeling in arthritis, thus not only blocking bone erosion caused by osteoclasts, but also inducing new bone formation by osteoblasts, in order to restore bone mass. While looking for unknown pathways involved in RA bone metabolism, some clinical evidences, together with few experimental studies and our previous results led us to hypothesize an involvement of the neurotransmitter dopamine in bone erosion in RA. Dopamine (DA) is a neurotransmitter (a chemical messenger) of the central nervous system controlling movement, emotion, cognition, and neuroendocrine interactions. Recent evidence supports a key role of dopamine in the modulation of immune response. Our hypothesis was that dopamine is involved in bone metabolism in RA. Main goal of this project was therefore to characterize the influence of the dopaminergic pathway on bone metabolism in RA and to identify its potential as therapeutic target towards a bone protective agent.
Data: CORDIS, © European Union
Project objective
Rheumatoid arthritis (RA) is associated with local bone erosion and systemic osteoporosis, which leads to severe disability and low quality of life. Although treatment with biologics can reduce bone loss by inhibiting inflammation, biologics are not able to achieve bone repair and some patients do not respond sufficiently to the treatment. Therefore, an efficient long-term therapeutic approach to target bone erosion and osteopenia still need to be established. Here, we describe a possible involvement of the neurotransmitter dopamine (DA) in bone metabolism and how we aim to use this new pathway to control bone erosion and restore bone mass in RA.The involvement of DA on joint inflammation in RA was demonstrated in vitro and in vivo, and an elevated concentration of DA in the synovial fluid of RA patients was also described. Moreover, we recently described that DA is produced in RA synovial tissue and can act in an autocrine/paracrine manner. However, it is still unclear which role local DA can exert on bone erosion in RA. We performed preliminary experiments and could confirm the presence of DRs in RA bone remodeling zone and in osteoblasts isolated from RA. Moreover, DR activation stimulated IL-6. This confirms the active role of local DA also on bone metabolism in RA.Goal of the present study is therefore to elucidate the mechanisms of action of DA in bone remodeling in RA, in order to find out how to modulate this pathway to control bone erosion and stimulate bone formation in RA. Specifically, we will address the following issues: 1) To identify the mechanisms responsible for DRs expression in RA bone remodeling zone, 2) To define mechanisms of action of DRs on bone metabolism in the context of RA 3) To prove the clinical applicability of DA modulation in arthritic joints towards an anti-inflammatory and bone-protective path. Final goal of this project is to establish a new therapeutic approach to block bone erosion and restore bone mass in RA.
Original text from CORDIS.
Participants
- FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ EV · DortmundCoordinatorGermany
Links
Data: CORDIS, © European Union